---
url: https://www.npr.org/2025/12/12/nx-s1-5639883/fda-testosterone-treatment-martin-makary
title: Testosterone levels have declined in men. Here's what the FDA wants to do about
  it
publisher: npr
usage: rejected
initial_rank: 4
---
## Article summary
The FDA is considering loosening restrictions on testosterone treatments due to a perceived decline in testosterone levels among men in the U.S. FDA Commissioner Martin Makary discussed this initiative with NPR's Steve Inskeep, highlighting that approximately one-third of men with low testosterone may experience symptoms such as reduced mood and vitality. Makary acknowledged that the evidence and data surrounding these associations are not yet fully defined. The FDA convened a panel of health experts to explore and advocate for the potential health benefits of testosterone therapies for men. The agency aims to address the stigma often associated with testosterone use and improve medical access to these treatments. Makary emphasized the FDA's desire to re-evaluate current policies regarding testosterone accessibility. The conversation touched upon the broader implications of declining testosterone levels and the FDA's role in promoting men's health. This push signifies a potential shift in how the medical community approaches testosterone deficiency and its management. The FDA's stance suggests a move towards greater consideration of testosterone as a therapeutic option for a wider range of men experiencing related symptoms.
